Highlights of weekly biotech stock moves

Almirall S.A. (Madrid:ALM) was off €0.10 to €10.08 last week on a double dose of negative news in Germany. The country's Federal Joint Committee (G-BA) said Bretaris/Eklira Genuiar aclidinium bromide has "no additional benefit" over Spiriva HandiHaler tiotropium for chronic obstructive pulmonary disease (COPD).

Also, the company said the price in Germany for Sativex to treat spasticity due to multiple sclerosis (MS) is "unacceptable." An independent arbitration board determined the price for Sativex after Almirall and Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband) failed to agree on a price during negotiations (see B12)...